Privia Health Group (PRVA)
(Delayed Data from NSDQ)
$18.26 USD
+0.27 (1.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.24 -0.02 (-0.11%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Privia Health (PRVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$28.47 | $45.00 | $21.00 | 58.25% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Privia Health comes to $28.47. The forecasts range from a low of $21.00 to a high of $45.00. The average price target represents an increase of 58.25% from the last closing price of $17.99.
Analyst Price Targets (19)
Broker Rating
Privia Health currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.26 a month ago based on 19 recommendations.
Of the 20 recommendations deriving the current ABR, 17 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85% and 5% of all recommendations. A month ago, Strong Buy made up 84.21%, while Buy represented 5.26%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 16 | 16 | 16 | 17 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.26 | 1.26 | 1.17 | 1.06 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/19/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
3/1/2024 | Stephens | Jeffrey Garro | Strong Buy | Strong Buy |
2/29/2024 | Truist Securities | Jailendra Singh | Strong Buy | Strong Buy |
2/28/2024 | Evercore Partners | Elizabeth Anderson | Strong Buy | Strong Buy |
1/30/2024 | BTIG | David M Larsen | Strong Buy | Strong Buy |
12/6/2023 | JMP Securities | Constantine Kyriakos Davides | Not Available | Strong Buy |
11/3/2023 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
11/3/2023 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.26 |
# of Recs in ABR | 20 |
Average Target Price | $28.47 |
LT Growth Rate | 27.80% |
Industry | Medical Info Systems |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | 0.05 |